Chimeric Antigen Receptor T-Cell Therapies for Cancer
A Practical Guide
- 1st Edition - November 30, 2019
- Imprint: Elsevier
- Editors: Daniel W. Lee, Nirali N. Shah
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 6 6 1 8 1 - 2
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 7 5 5 9 7 - 9
From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteFrom patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area.
- Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care.
- Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care.
- Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon.
- Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.
Introduction
1. When to Refer a Patient for CAR-T Cell Therapy
2. Optimizing the Apheresis Product
3. CAR T Cells: Cell Processing Laboratory Considerations
4. Peri-CAR-T Cell Management
5. Management of Cytokine Release Syndrome
6. Special Considerations for ICU Management of Patients Receiving CAR Therapy
7. Neurotoxicities After CAR-T Cell Immunotherapy
8. Hematologic and Non-CRS Toxicities
9. Response Assessment and PosteCAR-T Cell Therapy Management
10. Relapse Management and Role for Consolidative Hematopoietic Stem Cell Transplantation Following CAR-T Cell Therapy
11. Promising Chimeric Antigen Receptors for Non-B Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas
12. CAR T Cell Therapy for CNS Malignancies
13. CAR 2.0: The Next Generation of Synthetic ReceptoreBased Cellular Therapy for Cancer
- Edition: 1
- Published: November 30, 2019
- Imprint: Elsevier
- No. of pages: 244
- Language: English
- Paperback ISBN: 9780323661812
- eBook ISBN: 9780323755979
NS
Nirali N. Shah
Affiliations and expertise
Lasker Clinical Research Scholar, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, United StatesRead Chimeric Antigen Receptor T-Cell Therapies for Cancer on ScienceDirect